Vaxcyte to Present at Annual Healthcare Conference

The clinical-stage vaccine company will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference.

Apr. 8, 2026 at 6:03am

Got story updates? Submit your updates here. ›

A minimalist design in the style of Keith Haring, with a glowing neon outline of a syringe or vaccine vial against a dark background, emphasizing the shape and electricity of the medical device.Vaxcyte's cutting-edge vaccine technology aims to provide broader protection against pneumococcal disease.San Carlos Today

Vaxcyte, Inc., a clinical-stage vaccine innovation company, announced that the company's management will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2026. The live webcast of the fireside chat will be available through the Investors & Media section of Vaxcyte's website.

Why it matters

As a clinical-stage vaccine company, Vaxcyte's participation in major healthcare conferences provides an opportunity to share updates on the development of its pipeline of innovative vaccine candidates, including VAX-31, VAX-24, and VAX-XL, which are designed to offer broader protection against pneumococcal disease.

The details

Vaxcyte is developing a portfolio of advanced pneumococcal conjugate vaccine (PCV) candidates that aim to provide more comprehensive coverage against invasive pneumococcal disease compared to current standard-of-care PCVs. The company's presentation at the Needham conference will likely focus on the progress of its lead PCV candidates, VAX-31 and VAX-24, which are currently in clinical trials.

  • The fireside chat will take place on Tuesday, April 14, 2026 at 2:15 p.m. ET / 11:15 a.m. PT.
  • The live webcast will be available through the Investors & Media section of Vaxcyte's website.

The players

Vaxcyte, Inc.

A clinical-stage vaccine innovation company developing advanced pneumococcal conjugate vaccine candidates.

VAX-31

Vaxcyte's 31-valent pneumococcal conjugate vaccine candidate being evaluated in Phase 3 adult and Phase 2 infant clinical trials.

VAX-24

Vaxcyte's 24-valent pneumococcal conjugate vaccine candidate designed to cover more serotypes than any infant PCV on the market.

Got photos? Submit your photos here. ›

What’s next

Investors and the public will be able to access the live webcast of Vaxcyte's fireside chat presentation on the company's website, and a replay will be available for approximately 30 days after the event.

The takeaway

Vaxcyte's participation in the Needham Virtual Healthcare Conference underscores the company's commitment to advancing its innovative pneumococcal vaccine pipeline and engaging with the investment community to share updates on its progress.